JP2018533570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533570A5 JP2018533570A5 JP2018520389A JP2018520389A JP2018533570A5 JP 2018533570 A5 JP2018533570 A5 JP 2018533570A5 JP 2018520389 A JP2018520389 A JP 2018520389A JP 2018520389 A JP2018520389 A JP 2018520389A JP 2018533570 A5 JP2018533570 A5 JP 2018533570A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amino acid
- absent
- peptide according
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 54
- 235000001014 amino acid Nutrition 0.000 claims 22
- 150000001413 amino acids Chemical class 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 229940127089 cytotoxic agent Drugs 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 231100000433 cytotoxic Toxicity 0.000 claims 4
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 230000001472 cytotoxic effect Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000032823 cell division Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- XUNKPNYCNUKOAU-VXJRNSOOSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]a Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XUNKPNYCNUKOAU-VXJRNSOOSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 108700005087 Homeobox Genes Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 229920006317 cationic polymer Polymers 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 229920001519 homopolymer Polymers 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108010011110 polyarginine Proteins 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1518700.8 | 2015-10-21 | ||
| GB1518700.8A GB2543550A (en) | 2015-10-21 | 2015-10-21 | Peptides |
| PCT/GB2016/053282 WO2017068353A1 (en) | 2015-10-21 | 2016-10-20 | Peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018533570A JP2018533570A (ja) | 2018-11-15 |
| JP2018533570A5 true JP2018533570A5 (https=) | 2020-07-30 |
Family
ID=55131441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018520389A Pending JP2018533570A (ja) | 2015-10-21 | 2016-10-20 | ペプチド |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10494412B2 (https=) |
| EP (2) | EP3364992B1 (https=) |
| JP (1) | JP2018533570A (https=) |
| KR (1) | KR20180080217A (https=) |
| CN (1) | CN108430491A (https=) |
| AU (1) | AU2016341494A1 (https=) |
| BR (1) | BR112018008136A2 (https=) |
| CA (1) | CA3002739A1 (https=) |
| EA (1) | EA201890900A1 (https=) |
| ES (1) | ES2775740T3 (https=) |
| GB (1) | GB2543550A (https=) |
| MX (1) | MX2018004930A (https=) |
| WO (1) | WO2017068353A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121287874B (zh) * | 2025-12-12 | 2026-03-17 | 广州飞来爱生命科技有限公司 | 一种治疗前列腺疾病的间充质干细胞组合物及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| AU1681095A (en) * | 1994-01-14 | 1995-08-01 | Matthias Rath | Hydrophilic signal oligopeptides and methods of therapeutic use |
| US5608082A (en) | 1994-07-28 | 1997-03-04 | Agouron Pharmaceuticals, Inc. | Compounds useful as antiproliferative agents and GARFT inhibitors |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| SI1255752T1 (sl) | 2000-02-15 | 2007-12-31 | Pharmacia & Upjohn Co Llc | S pirolom substituirani zaviralci 2-indolinon protein kinaza |
| BRPI0116728B1 (pt) | 2001-01-05 | 2018-10-30 | Pfizer Inc. | anticorpos para receptor de fator de crescimento i semelhante à insulina |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| GB0229151D0 (en) * | 2002-12-13 | 2003-01-15 | St Georges Entpr Ltd | Product and method |
| US7259266B2 (en) | 2003-03-31 | 2007-08-21 | Pharmacia Corporation | Benzopyran compounds useful for treating inflammatory conditions |
| US20050148627A1 (en) | 2003-03-31 | 2005-07-07 | Jeffery Carter | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions |
| WO2007000601A2 (en) * | 2005-06-29 | 2007-01-04 | St Georges Enterprises Limited | Gene regulation |
| US7928186B2 (en) * | 2006-08-02 | 2011-04-19 | Phoenix Pharmaceuticals, Inc. | Cell permeable bioactive peptide conjugates |
| PT2252627T (pt) * | 2008-01-24 | 2017-07-24 | Esperance Pharmaceuticals | Constructos de fusão de domínio lítico e métodos para produzir e utilizar os mesmos |
| JP6943759B2 (ja) | 2017-12-28 | 2021-10-06 | 株式会社東海理化電機製作所 | シフト装置 |
-
2015
- 2015-10-21 GB GB1518700.8A patent/GB2543550A/en not_active Withdrawn
-
2016
- 2016-10-20 BR BR112018008136A patent/BR112018008136A2/pt not_active Application Discontinuation
- 2016-10-20 JP JP2018520389A patent/JP2018533570A/ja active Pending
- 2016-10-20 CA CA3002739A patent/CA3002739A1/en not_active Abandoned
- 2016-10-20 KR KR1020187012506A patent/KR20180080217A/ko not_active Withdrawn
- 2016-10-20 EP EP16801003.1A patent/EP3364992B1/en active Active
- 2016-10-20 CN CN201680074733.7A patent/CN108430491A/zh active Pending
- 2016-10-20 EP EP19200535.3A patent/EP3610883A1/en not_active Withdrawn
- 2016-10-20 ES ES16801003T patent/ES2775740T3/es active Active
- 2016-10-20 MX MX2018004930A patent/MX2018004930A/es unknown
- 2016-10-20 WO PCT/GB2016/053282 patent/WO2017068353A1/en not_active Ceased
- 2016-10-20 US US15/770,023 patent/US10494412B2/en active Active
- 2016-10-20 AU AU2016341494A patent/AU2016341494A1/en not_active Abandoned
- 2016-10-20 EA EA201890900A patent/EA201890900A1/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021100937A5 (https=) | ||
| JP7175506B2 (ja) | 低血圧治療のための単独または併用使用されるアンギオテンシンｉｉ | |
| JP2021046436A (ja) | ペプチド模倣大環状分子およびその製剤 | |
| IL308807B2 (en) | Combination therapy for treating cancer | |
| Chen et al. | Role of RIPK3‑CaMKII‑mPTP signaling pathway‑mediated necroptosis in cardiovascular diseases | |
| TWI633887B (zh) | 用於預防及／或治療多囊性腎臟病之藥物 | |
| JP2015057436A5 (https=) | ||
| JP2019529541A5 (https=) | ||
| JP2012067116A5 (https=) | ||
| RU2019110150A (ru) | Стабилизаторы тучных клеток лечения гиперцитокинемии и вирусной инфекции | |
| JP2010536714A5 (https=) | ||
| JP2020521797A5 (https=) | ||
| JP2019515908A5 (https=) | ||
| JP2012115277A5 (https=) | ||
| JP2016517421A5 (https=) | ||
| JPWO2019156137A5 (https=) | ||
| JP2018516944A5 (https=) | ||
| US20160175286A1 (en) | Selective at2 receptor agonists for use in treatment of cachexia | |
| JP2018533570A5 (https=) | ||
| JP2013542196A5 (https=) | ||
| JP2014520764A5 (https=) | ||
| US20230338348A1 (en) | Renin-angiotensin system (ras) modulators for treatment of viral infections, pharmaceutical compositions including the same, and methods of treating using the same | |
| KR20040101418A (ko) | 신경영양 인자 생산 촉진제 | |
| JP2015524431A5 (ja) | 視神経損傷、眼虚血または眼の再灌流傷害を治療または予防する医薬 | |
| RU2018132694A (ru) | Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста |